Pharmacological and safety profile of dexlansoprazole: A new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region

Khean Lee Goh, Myung Gyu Choi, Ping I. Hsu, Hoon-Jai Chun, Varocha Mahachai, Udom Kachintorn, Somchai Leelakusolvong, Nayoung Kim, Abdul Aziz Rani, Benjamin C.Y. Wong, Justin Wu, Cheng Tang Chiu, Vikram Shetty, Joseph C. Bocobo, Melchor M. Chan, Jaw Town Lin

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as increased healthcare use. Proton pump inhibitors (PPIs) are currently the most effective treatment for gastroesophageal reflux disease. However, there are limitations associated with these drugs in terms of partial and non-response. Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration. Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms. Dexlansoprazole has also been shown to achieve good plasma concentration regardless of administration with food, providing flexible dosing. Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed. This review discusses the role of the new generation PPI, dexlansoprazole, in the treatment of gastroesophageal reflux disease in Asia.

Original languageEnglish
Pages (from-to)355-366
Number of pages12
JournalJournal of Neurogastroenterology and Motility
Volume22
Issue number3
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Dexlansoprazole
clopidogrel
Proton Pump Inhibitors
Gastroesophageal Reflux
Pharmacology
Safety
Esophagitis
Therapeutics
Pharmaceutical Preparations
Healthy Volunteers
Blood Platelets
Delivery of Health Care
Food

Keywords

  • Asia
  • Delayed-action preparations
  • Dexlansoprazole
  • Gastroesophageal reflux
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Clinical Neurology
  • Gastroenterology

Cite this

Pharmacological and safety profile of dexlansoprazole : A new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region. / Goh, Khean Lee; Choi, Myung Gyu; Hsu, Ping I.; Chun, Hoon-Jai; Mahachai, Varocha; Kachintorn, Udom; Leelakusolvong, Somchai; Kim, Nayoung; Rani, Abdul Aziz; Wong, Benjamin C.Y.; Wu, Justin; Chiu, Cheng Tang; Shetty, Vikram; Bocobo, Joseph C.; Chan, Melchor M.; Lin, Jaw Town.

In: Journal of Neurogastroenterology and Motility, Vol. 22, No. 3, 01.01.2016, p. 355-366.

Research output: Contribution to journalReview article

Goh, KL, Choi, MG, Hsu, PI, Chun, H-J, Mahachai, V, Kachintorn, U, Leelakusolvong, S, Kim, N, Rani, AA, Wong, BCY, Wu, J, Chiu, CT, Shetty, V, Bocobo, JC, Chan, MM & Lin, JT 2016, 'Pharmacological and safety profile of dexlansoprazole: A new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region', Journal of Neurogastroenterology and Motility, vol. 22, no. 3, pp. 355-366. https://doi.org/10.5056/jnm15150
Goh, Khean Lee ; Choi, Myung Gyu ; Hsu, Ping I. ; Chun, Hoon-Jai ; Mahachai, Varocha ; Kachintorn, Udom ; Leelakusolvong, Somchai ; Kim, Nayoung ; Rani, Abdul Aziz ; Wong, Benjamin C.Y. ; Wu, Justin ; Chiu, Cheng Tang ; Shetty, Vikram ; Bocobo, Joseph C. ; Chan, Melchor M. ; Lin, Jaw Town. / Pharmacological and safety profile of dexlansoprazole : A new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region. In: Journal of Neurogastroenterology and Motility. 2016 ; Vol. 22, No. 3. pp. 355-366.
@article{889ba64963ee453d9e1fbcb0c18ebb0b,
title = "Pharmacological and safety profile of dexlansoprazole: A new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region",
abstract = "Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as increased healthcare use. Proton pump inhibitors (PPIs) are currently the most effective treatment for gastroesophageal reflux disease. However, there are limitations associated with these drugs in terms of partial and non-response. Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration. Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms. Dexlansoprazole has also been shown to achieve good plasma concentration regardless of administration with food, providing flexible dosing. Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed. This review discusses the role of the new generation PPI, dexlansoprazole, in the treatment of gastroesophageal reflux disease in Asia.",
keywords = "Asia, Delayed-action preparations, Dexlansoprazole, Gastroesophageal reflux, Proton pump inhibitors",
author = "Goh, {Khean Lee} and Choi, {Myung Gyu} and Hsu, {Ping I.} and Hoon-Jai Chun and Varocha Mahachai and Udom Kachintorn and Somchai Leelakusolvong and Nayoung Kim and Rani, {Abdul Aziz} and Wong, {Benjamin C.Y.} and Justin Wu and Chiu, {Cheng Tang} and Vikram Shetty and Bocobo, {Joseph C.} and Chan, {Melchor M.} and Lin, {Jaw Town}",
year = "2016",
month = "1",
day = "1",
doi = "10.5056/jnm15150",
language = "English",
volume = "22",
pages = "355--366",
journal = "Journal of Neurogastroenterology and Motility",
issn = "2093-0879",
publisher = "Korean Society of Neurogastroenterology and Motility",
number = "3",

}

TY - JOUR

T1 - Pharmacological and safety profile of dexlansoprazole

T2 - A new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region

AU - Goh, Khean Lee

AU - Choi, Myung Gyu

AU - Hsu, Ping I.

AU - Chun, Hoon-Jai

AU - Mahachai, Varocha

AU - Kachintorn, Udom

AU - Leelakusolvong, Somchai

AU - Kim, Nayoung

AU - Rani, Abdul Aziz

AU - Wong, Benjamin C.Y.

AU - Wu, Justin

AU - Chiu, Cheng Tang

AU - Shetty, Vikram

AU - Bocobo, Joseph C.

AU - Chan, Melchor M.

AU - Lin, Jaw Town

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as increased healthcare use. Proton pump inhibitors (PPIs) are currently the most effective treatment for gastroesophageal reflux disease. However, there are limitations associated with these drugs in terms of partial and non-response. Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration. Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms. Dexlansoprazole has also been shown to achieve good plasma concentration regardless of administration with food, providing flexible dosing. Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed. This review discusses the role of the new generation PPI, dexlansoprazole, in the treatment of gastroesophageal reflux disease in Asia.

AB - Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as increased healthcare use. Proton pump inhibitors (PPIs) are currently the most effective treatment for gastroesophageal reflux disease. However, there are limitations associated with these drugs in terms of partial and non-response. Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration. Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms. Dexlansoprazole has also been shown to achieve good plasma concentration regardless of administration with food, providing flexible dosing. Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed. This review discusses the role of the new generation PPI, dexlansoprazole, in the treatment of gastroesophageal reflux disease in Asia.

KW - Asia

KW - Delayed-action preparations

KW - Dexlansoprazole

KW - Gastroesophageal reflux

KW - Proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84977577189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977577189&partnerID=8YFLogxK

U2 - 10.5056/jnm15150

DO - 10.5056/jnm15150

M3 - Review article

AN - SCOPUS:84977577189

VL - 22

SP - 355

EP - 366

JO - Journal of Neurogastroenterology and Motility

JF - Journal of Neurogastroenterology and Motility

SN - 2093-0879

IS - 3

ER -